<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548949</url>
  </required_header>
  <id_info>
    <org_study_id>B2061143</org_study_id>
    <nct_id>NCT02548949</nct_id>
  </id_info>
  <brief_title>Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ</brief_title>
  <acronym>PMS</acronym>
  <official_title>KOREAN POST MARKETING SURVEILLANCE TO OBSERVE EFFECTIVENESS AND SAFETY OF PRISTIQ (REGISTERED) IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On 6 Feb 2014, Pristiq was approved for the treatment of Major Depressive Disorder(MDD) in
      Korea. In accordance with the Standards for Re-examination of New Drug, it is required to
      conduct a PMS for 600 patients by 5 Feb 2020. Post marketing surveillance is required to
      determine any problems or questions associated with Pristiq after marketing, with regard to
      the following clauses under conditions of general clinical practice. Therefore, through this
      study, effectiveness and safety of pristiq will be observed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine any problems or questions associated with Pristiq
      after marketing, with regard to the following clauses under conditions of general clinical
      practice, in compliance with the regulation &quot;Re-examination guideline of new drugs (Ministry
      of Food and Drug Safety Notification 2013-251, 2013.12.20)&quot;.

        1. Serious adverse event/adverse drug reaction

        2. Unexpected adverse event/adverse drug reaction that have not been reflected in the
           approved drug label.

        3. Known adverse drug reaction

        4. Non-serious adverse drug reaction

        5. Other safety and effectiveness information
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2016</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events categorized according to physical organ and disease/symptom</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire of overall effectiveness of treatment</measure>
    <time_frame>8 week</time_frame>
    <description>rated as either improved, no change, worse, or unevaluable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events categorized according to physical organ and disease/symptom</measure>
    <time_frame>6 month</time_frame>
    <description>60 subjects among 600 subjects will be enrolled in long-term use study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of overall effectiveness of treatment</measure>
    <time_frame>6 month</time_frame>
    <description>rated as either improved, no change, worse, or unevaluable
60 subjects among 600 subjects will be enrolled in long-term use study</description>
  </secondary_outcome>
  <enrollment type="Actual">704</enrollment>
  <condition>Major Depressive Disorder</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Retention of biospecimen is not needed necessarily. If the investigator check blood sample
      under routine practice during the study, investigator record results of blood sampling, such
      as CBC and blood chemistry.

      Full lists of recordings are following : Hemoglobin, Hematocrit, RBC, WBC, Platelets, Sodium,
      Potassium, BUN, Creatinine, Calcium, Total Bilirubin, SGOT/AST, SGPT/ALT, Cholesterol.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults 19 years of age or older, who have been received at least one dose of PRISTIQ® for
        the treatment of Major depressive disorder (MDD). The study population would be enrolled in
        multi-center in which subjects are administered PRISTIQ as part of routine practice at
        Korean health care centers by accredited psychiatrists.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults 19 years of age or older, who have been received at least one dose of PRISTIQ®
             for the treatment of Major depressive disorder (MDD).

          2. Patients who have been received for the first time after signed the 'data privacy
             statement'

        Exclusion Criteria:

        Patients to whom PRISTIQ® is contraindicated as per the local labeling;

          1. Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any
             excipients in the PRISTIQ® formulation.

          2. Serotonin syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders
             with PRISTIQ® or Do not use PRISTIQ® within 14 days of stopping an MAOI intended to
             treat psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheonbuk-do</state>
        <zip>362-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Chungju Hospital / Department of Psychiatry</name>
      <address>
        <city>Chungju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>27376</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital/Department of Neuropsychiatry</name>
      <address>
        <city>Hwaseong-si</city>
        <state>Gyeonggi Province</state>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-Si</city>
        <state>Gyeonggi-do</state>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roa Neurology Clinic/Neurology</name>
      <address>
        <city>Bundang-gu, Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13618</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bong Seng Memorial Hospital</name>
      <address>
        <city>Busan</city>
        <zip>601-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital-Hallym University</name>
      <address>
        <city>Gangwon-do</city>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Center</name>
      <address>
        <city>Jeonju</city>
        <zip>560-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center, Eulji University</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong Department of Psychiatry</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B2061143</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

